← Back to Screener
Tyra Biosciences, Inc. Common Stock (TYRA)
Price$26.64
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)10.16%
Price vs S&P 500 (4W)-22.37%
VGM Score51.34
Market Capitalization$1.61B
All Metrics
Book Value / Share (Quarterly)$6.52
P/TBV (Annual)1.87x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.72
Price vs S&P 500 (YTD)-6.83%
EPS (TTM)$-2.17
10-Day Avg Trading Volume0.82M
EPS Excl Extra (TTM)$-2.17
EPS (Annual)$-2.01
ROI (Annual)-46.28%
Cash / Share (Quarterly)$6.45
ROA (Last FY)-42.44%
EBITD / Share (TTM)$-2.36
ROE (5Y Avg)-27.10%
Cash Flow / Share (Annual)$-1.77
P/B Ratio4.16x
P/B Ratio (Quarterly)5.88x
Net Income / Employee (Annual)$-1,378,700
ROA (TTM)-39.79%
EPS Incl Extra (Annual)$-2.01
Current Ratio (Annual)14.67x
Quick Ratio (Quarterly)20.06x
3-Month Avg Trading Volume0.98M
52-Week Price Return161.95%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.18
52-Week High$40.65
EPS Excl Extra (Annual)$-2.01
CapEx CAGR (5Y)-14.58%
26-Week Price Return18.09%
Quick Ratio (Annual)14.25x
13-Week Price Return-22.87%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.49x
Enterprise Value$1.53B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.77
3-Month Return Std Dev52.45%
Net Income / Employee (TTM)$-1,507,000
ROE (Last FY)-46.28%
EPS Basic Excl Extra (Annual)$-2.01
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.17
ROI (TTM)-42.66%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.09
Price vs S&P 500 (52W)137.58%
Year-to-Date Return1.33%
5-Day Price Return-12.34%
EPS Normalized (Annual)$-2.01
ROA (5Y Avg)-25.24%
Month-to-Date Return-20.26%
Cash Flow / Share (TTM)$-1.38
EBITD / Share (Annual)$-2.22
ROI (5Y Avg)-27.10%
EPS Basic Excl Extra (TTM)$-2.17
P/TBV (Quarterly)2.17x
P/B Ratio (Annual)5.41x
Book Value / Share (Annual)$4.83
Price vs S&P 500 (13W)-31.13%
Beta0.80x
Revenue / Share (TTM)$0.00
ROE (TTM)-42.66%
52-Week Low$8.98
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.64est. -0.60
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.38
4.39
4.39
4.40
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TYRATyra Biosciences, Inc. Common Stock | — | — | C | $26.64 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting FGFR (Fibroblast Growth Factor Receptor) biology through its proprietary SNAP platform, which enables rapid drug discovery with optimized potency, selectivity, and safety profiles. The pipeline includes three clinical-stage small molecules (TYRA-300, TYRA-200, TYRA-430) designed to overcome the toxicity and resistance liabilities of first-generation FGFR inhibitors.